Flagship Harbor Advisors LLC Acquires Shares of 5,842 DexCom, Inc. (NASDAQ:DXCM)

Flagship Harbor Advisors LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 5,842 shares of the medical device company's stock, valued at approximately $454,000.

Other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock valued at $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Jennison Associates LLC lifted its stake in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after acquiring an additional 6,544,102 shares during the period. Groupama Asset Managment boosted its holdings in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock valued at $1,912,000 after acquiring an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after acquiring an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of DexCom by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock valued at $183,298,000 after purchasing an additional 288,381 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DXCM. Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their price objective on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Leerink Partners lowered their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Finally, Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus price target of $99.29.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.30% of the company's stock.

DexCom Stock Performance

DXCM stock traded down $1.54 during midday trading on Wednesday, reaching $86.82. The stock had a trading volume of 1,085,637 shares, compared to its average volume of 3,643,816. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a fifty day simple moving average of $80.00 and a two-hundred day simple moving average of $76.52. The stock has a market cap of $33.91 billion, a PE ratio of 51.92, a P/E/G ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.